

**AMENDMENTS TO THE CLAIMS**

Claims 1-14 (canceled).

Claim 15 (currently amended) A method of ~~determining the risk of~~  
~~developing~~ diagnosing a Wnt antagonist-associated lytic bone disease  
~~characterized by bone loss in a test an~~ individual, comprising said method  
~~comprises the step of:~~

examining the expression level of the human homologue of Dickkopf-  
1 (DKK-1) protein in said test individual, wherein an increased expression of said  
protein compared to that in a normal individual indicates that said test individual  
has the ~~risk of developing~~ Wnt antagonist-associated lytic bone disease.

Claim 16-17 (canceled).

Claim 18 (previously presented) The method of claim 15, wherein  
said expression level is determined by enzyme-linked immunosorbent assays.

Claim 19 (currently amended) The method of claim 15, wherein said  
test individual has multiple myeloma.

Claims 20-38 (canceled).